Healthcare
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to
About this update from Evotec Se
SEATTLE and HAMBURG, Germany, June 30, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to enable significantly faster and more cost-effective deployment than traditional manufacturing expansion. Linda Zuckerman, PhD, EVP Global Head of Just – Evotec Biologics commented: "J.TRAIN is a disruptive opportunity for industry to increase capacity and manufacture biologics at reduced costs and improved productivity, with deployment in as little as 18 months. It exemplifies the strategic shift in Just – Evotec Biologics toward a rapidly deployable, capital-lighter and technology-focused business model. We now combine technology licensing with process design and engineering capabilities, enabling the fast establishment and implementation of the most advanced continuous manufacturing processes, giving companies greater, tunable control over clinical and commercial materials. The model was validated by our December 2025 transaction with Sandoz, which included the provision of a manufacturing facility alongside a license to our proprietary manufacturing technology, demonstrating both its feasibility and scalability." Unveiled in April 2026 at the INTERPHEX conference in New York City, J.TRAIN allows customers and partners to establish high-performance biologics manufacturing capacity on their own premises, effectively embedding advanced manufacturing capabilities directly into their operations. Proprietary automation scripts for continuous process control, as well as digital validation, documentation and training protocols are all designed to significantly streamline implementation and ensure regulatory readiness.